Larimar Therapeutics Inc (LRMR) Directors and Executive Officers

Officers & Directors

1. Joseph Truitt - Chairman, Board of Directors

2. Carole S. Ben-Maimon, M.D. - President, Chief Executive Officer and Director (principal executive officer)

3. Michael Celano - Chief Financial Officer (principal financial and accounting officer)

4. Frank E. Thomas - Director

5. Jonathan Leff - Director

6. Thomas E. Hamilton - Director

7. Jeffrey W. Sherman, M.D., FACP - Director ,

Larimar Therapeutics Inc currently has 71 employees.

News about Larimar Therapeutics Inc Key Personnel

Larimar Therapeutics Receives FDA's Stamp of Approval for Revolutionary FA Treatment in START Program

BALA CYNWYD, Pa., May 30, 2024 - Leading biotechnology company Larimar Therapeutics, Inc. (Nasdaq: LRMR) proudly announces its selection by the United States Food and Drug Administration (FDA) to participate in the pioneering Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. This significant milestone highlights Larimar s commitment to developing effective treatments for complex rare diseases. The FDA s endorsement of Larimar s breakthrough protein replacement therapy called nomlabofusp, designed to combat Friedreichs ataxia (FA), is expected to grant the company accelerated pathways towards pivotal study initiation and potential Biologics License Application (BLA) s...

Larimar Therapeutics' Groundbreaking Study Shows Promise in Rare Friedreich's Ataxia Treatment

Larimar Therapeutics Promising Phase 2 Study Indicates Potential Breakthrough in Friedreich s Ataxia Treatment
BALA CYNWYD, Pa. - Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, has announced positive top-line data from its Phase 2 dose exploration study of nomlabofusp (CTI-1601) in patients with Friedreich s ataxia (FA). This groundbreaking study offers hope for the thousands of individuals around the world affected by this rare disorder.
Friedreich s ataxia is a progressive neurodegenerative disease that primarily affects the nervous system and causes muscle weakness, loss of coordination, and impaired speech. Currently, ther...